[{"orgOrder":0,"company":"Royalsense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pantoprazole Sodium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Royalsense","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Royalsense \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Royalsense \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Domperidone

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Immuno-Oncology 360
Not Confirmed
Immuno-Oncology 360
Not Confirmed

Details : OPENTOP D (pantoprazole Sodium and domperidone) Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD.

Product Name : Opentop D

Product Type : Small molecule

Upfront Cash : Not Applicable

August 28, 2024

Lead Product(s) : Pantoprazole Sodium,Domperidone

Therapeutic Area : Gastroenterology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank